India, Nov. 15 -- Johnson & Johnson (JNJ) is considering the acquisition of privately held eye disease drug developer Ollin Biosciences in a deal valued at up to $3.4 billion, the Financial Times reported, citing people familiar with the matter.
Ollin Biosciences, backed by Arch Venture Partners and Mubadala Capital, is a clinical-stage biopharmaceutical company developing treatments for vision-related eye diseases, including diabetic macular oedema (DME) and wet age-related macular degeneration (AMD).
The proposed transaction could include an upfront cash payment of about $2.2 billion, with an additional $1.2 billion tied to future milestone achievements. The deal could be announced as soon as Monday, sources said, although ongoing discu...